CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback